ARTICLE SUMMARY:
Growth in China has slowed considerably of late, but the country’s economic woes actually present some unique opportunities for well-positioned medtech companies, particularly those with established strategies aimed at localizing their China operations.
Although China is entering into a period of slower growth and economic uncertainty—heralded this summer by several weeks of extreme volatility in the country’s stock market—most of the top US multinational medical device companies appear to be weathering the storm well, with minimal impact on the bottom line thus far.
